Prima BioMed EBITDA Margin 2010-2021 | IMMP
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Prima BioMed (IMMP) over the last 10 years. The current EBITDA margin for Prima BioMed as of December 31, 2021 is .
| Prima BioMed EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.254B |
$0.003B |
|
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
|
